MAPK14 Antibodies

Mitogen-activated protein kinase 14 (MAPK14)

Serine/threonine kinase which functions as an essential component of the MAP kinase signal transduction pathway. MAPK14 is one of the four p38 MAPKs which play an significant role in the cascades of cellular responses evoked by extracellular stimuli such as proinflammatory cytokines or physical strain leading to direct activation of transcription factors.

Accordingly, p38 MAPKs phosphorylate a wide assortment of proteins and it has been estimated that they might have approximately 200 to 300 substrates each. A few of the targets are downstream kinases that are activated through phosphorylation and additional phosphorylate additional targets.

Gene Information

Human
Gene Name:	MAPK14
Uniprot:	Q16539
Entrez:	1432

Family

Belongs to:
protein kinase superfamily

Alternative Names

MAPK14; p38 alpha; SAPK2a

Molecular Weight

Mass (kDA):
41.293 kDA

Genomic Context

Human
Location:	6p21.31
Sequence:	6; NC_000006.12 (36027677..36122964)

Tissue Specificity

Brain, heart, placenta, pancreas and skeletal muscle. Expressed to a lesser extent in lung, liver and kidney.

Subcellular Localizations

Cytoplasm. Nucleus.

Diseases

• Malignant Neoplasms
• Neoplasms
• Inflammation
• Inflammatory Response
• Carcinoma
• Colorectal Cancer
• Rectal Carcinoma
• Mammary Neoplasms
• Cell Transformation, Neoplastic
• Glioblastoma
• Myeloproliferative Disease
• Cholangiocarcinoma

• Hypoxia
• Infertility
• Tumor Angiogenesis
• Thrombocytosis
• Liver Carcinoma
• Malignant Paraganglionic Neoplasm
• Chronic Obstructive Airway Disease

Interacting Proteins

• AKT1
• DUSP1
• DUSP9
• MAP2K3
• MAPK1

• MAPK3
• MAPKAPK2
• MAPKAPK3
• MKNK1
• MKNK2

• NUP153
• PPM1A
• PTPRR
• RB1
• RPS6KA4

• SUPT20H
• TAB1
• TSC1
• ZFP36L1
• ZNHIT1

Pathways

• Cell Proliferation
• Cell Cycle
• Cell Death
• Secretion
• Inflammatory Response
• Cell Migration
• Cell Differentiation
• Immune Response
• Rna Interference
• Embryo Development
• Oocyte Maturation
• Regeneration
• Transport

• Oxidative Phosphorylation
• Translation
• Wound Healing
• Induction Of Apoptosis
• Metaphase
• Intracellular Signal Transduction
• Localization

PTMs

• Phosphorylation

• Cleavage

• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/MAPK14

Best Uses Of The MAPK14 Marker From Boster Bio

Research on cancer is very relevant because the MAPK14 genes is an important marker. It is an important component of cancer cell growth. It is essential to detect this gene in cancer cells for understanding the causes and possible treatment options. Boster's gene infographics, which include basic information about each of the genes, are useful for this purpose. This infographic covers every human and mouse gene, and features a search bar for finding the gene of interest.

Anti-p-MAPK14 (Tyr180)

Anti-p-MAPK14 (Tyer180) from Boster Bio reacts with human P38 MAPK. It can be stored at -20°C up to one year. Boster Bio Anti–p-MAPK14 Antibody can be purchased in 10 mM Hepez and 100 mg/ml BSA. To prevent cross-reactivity, you can buy the separate blocker peptide.

MAPK14, a key regulator of clathrinmediated EGFR internalization, is important. It also regulates RAB5A small GTPase. Phosphorylation (or phosphorylation) of MAPK14 regulates transmembrane proteins secretion and activates TGFalpha family binding ligands. If you plan on testing this antibody in cell-based assays, ensure that the secondary antibody is used.

MAP2Ks phosphorylate MAPK14. MAPK14 phosphorylation activates downstream protein kinases. It can also activate transcription elements via phosphorylation the TCR. MAPK14 phosphorylates many other targets. MAPK14's regulation of cellular responses is regulated by phosphorylation.

Anti-ROCK2

MAP kinase 14 or (MAPK14), is a protein that regulates cellular survival and growth. This marker is also known to be ERK2, mitogen activated protein kinase (or p42). The enzyme is expressed on multiple tissues and in numerous cell types. Boster Bio offers a variety MAPK14-related reagents including the monoclonal antibodies described below.

CX3CL1

Before we can understand the MAPK14 function, it is necessary to understand how it works. The MAPK14 gene plays a role in the metabolism and utilization of fatty acids. Therefore, it is not surprising that this gene is also involved with the metabolism and utilization of fats. Researchers recently discovered that this gene variant had a significant role in the risk of heart disease. This study revealed that it is an important biomarker in the prevention of cardiovascular disease.

The signaling molecule p38aMAP kinase is well-studied for almost two decades. It is composed of two domains: the N and C-terminal domains. The C-terminal domain is composed of ad helices and a catalyst site. Multiple studies have confirmed the structural flexibility this protein.

Genetic variations in MAPK14 are associated with increased risk of myeloperoxidase in individuals with dyslipidemia. It has been extensively studied how the gene is linked to metabolic syndrome. There are many studies that show it to be related to hyperlipidaemia as well as cardiovascular disease. These studies are the first to identify a genetic variation in the MAPK14 gene. However, the genetic variation must be carefully interpreted.

The expression of p38b MAPK signalling molecular is also affected by the MAPK14 genetic. This gene is also present in breast and ovarian tumors. Researchers used data from cBioportal. CanSar. and MEXPRESS to search for its expression among female cancers. The results showed that p38b expression was lower in breast carcinoma than in other types. However, there is a significant variation in methylation between cancer tissues.

Methods for detecting CX3CL1

The red bone broth of vertebrae contains cytokines, hormones, and enzymes that play important functions in the immune system. CX3CL1 happens to be one of these enzymes. Recent research has identified CX3CL1 to be a key mediator in tumor metastasis. Increased expression in BMECs may contribute to increased tumor metastasis of HCC cells. HCC cells show decreased anti-tumor activity if ADAM17 are inhibited.

CX3CL1 also increases VBMEC permeability. This pathway activates SrcGEFh2 (key component of a cell's lifetime) and ICAM-1 (key component of the cell's lifecycle). CX3CL1 also promotes cancer progression by increasing NSCLC cells adhesion to VBMECs. CX3CL1 is therefore a therapeutic drug target for lung cancer.

The authors first used two different cell lines, VBMECs and LBMECs, as well as a transwell culture system. Both cell lines were seeded into separate chambers of the Transwell system, and FITC-labeled dextran was added to the upper chamber. The lower chamber was filled with 100 uL medium. The cells were then incubated for 2 hours. A 100-uL sample was taken from both chambers. The fluorescence intensity of the cells was then calculated.

CX3CL1 is expressed in the retina to reduce microglial inflammation, prolong cone survival and decrease the number microglia in ONL. But, overexpression of full-length membrane-bound CX3CL1 has no effect. This difference could be due to the differences in the promoters of these two proteins. Moreover, sFKN has a higher promoter than human red opsin.

Applications of the MAPK14Marker

The MAPK14 Marker has several applications in vascular pathology, including detecting inflammatory cells and inhibiting apoptosis. This study was carried out on iSMC-MAPK14 mice that showed a significant reduction in CD45-positive cells in injured vessels. These findings have major implications for understanding the mechanisms of injury-inducedstenosis. The results show MAPK14 is required for inflammation. This includes the expression of proinflammatory gene and infiltration of blood vessels.

To validate the association between MAPK14 expression and disease/mutation types, three independent datasets were used. These datasets consisted of peripheral neutrophils derived from 93 patients, and bone marrow CD34+ cell derived from 65 patients. The MAPK14 expression was also examined in MPN subtypes. Normal donors were compared with patients with different mutation types. For correlation analysis, we also used the non-transformed MAPK14 expressed value.

Genetic variations in MAPK11 and MAPK14 have been associated with myeloperoxidase in a dyslipidemic population. These findings may have implications in the diagnosis of metabolic disease and cardiovascular disease. However, more research is needed in order to validate the gene variants linked with dyslipidemia. This study could lead to a better understanding about p38 mapkinase as well as the effects of apoptosis therapy.

MAPK14 regulates inflammation and activates a proinflammatory program in cultured VSMCs. It has been found that knockdown of MAPK14 reduced phosphorylated p65. Although MAPK14 knockdown did not affect the total protein p65, Bay117082, which is a selective inhibitor for the p65/NFKB pathway, prevented MAPK14 from being upregulated.